Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue | $66.9M | $87.3M | $72.5M | $59.0M | $62.0M |
| Cost of revenue | $35.7M | $49.6M | $40.8M | $34.7M | $40.4M |
| Gross profit | $31.2M | $37.7M | $31.7M | $24.4M | $21.8M |
| Gross margin | 46.6% | 43.2% | 43.8% | 41.3% | 35.2% |
| R&D | $4.0M | $5.2M | $4.4M | $4.0M | $3.6M |
| Operating income | $11.7M | $15.0M | $11.8M | $4.8M | $1.1M |
| EBITDA | $19.1M | $22.6M | $19.0M | $12.5M | $11.4M |
| Net income | $9.2M | $11.3M | $9.2M | $3.9M | $1.7M |
| Net margin | 13.7% | 12.9% | 12.6% | 6.6% | 2.7% |
| EPS (diluted) | 0.81 | 0.99 | 0.80 | 0.34 | 0.15 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $65M | $0.37 | $0.37–$0.37 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds PBBIF.
No tracked institution reports a position in PBBIF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2024-05-09 | $1.3000 | 2024-05-15 |
No one on the platform has traded PBBIF yet.
| $274M |
| — |
| HNSBFHansa Biopharma AB | $2.90 | +0.00% | $246M | — |
| OPORFhVIVO plc | $0.11 | +0.00% | $75M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.